Supplementary Figure S2 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco; Mirunalini Ravichandran; Jeff Lau; Anthony Lima; Jennifer A. Lacap; Pablo Saenz-Lopez Larrocha; Eva Lin; Julie Weng; Luca Gerosa; Thomas Hunsaker; Yang Xiao; Monika Miś; Charles Havnar; Wennie Chen; Kai Barck; Klára Tótpál; Oded Foreman; Nicole M. Sodir; Mark Merchant; Danilo Maddalo

doi:10.1158/0008-5472.30029573

Key Points

RIT1 M90I mutation significantly contributes to lung adenocarcinoma tumorigenesis and treatment resistance.
Ex vivo studies reveal that RIT1 knockout cell lines show specific therapeutic vulnerabilities to MAPK and PI3K inhibitors.
The methodology employed involved analyzing genetic knockouts in RIT1 cell lines to assess their responses to targeted therapies.
These findings suggest that targeting RIT1 could provide insights into overcoming resistance in lung adenocarcinoma treatments.

Implication

Ex vivo RIT1 cell lines exhibit Trp53 knockout and vulnerability to MAPK/PI3K inhibitors, highlighting treatment challenges.

Abstract

Supplementary Figure S2: Ex vivo RIT1 cell lines have Trp53 genetic knockout and therapeutic vulnerabilities include MAPK/PI3K inhibitors and statins.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

DiMarco et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b47 https://doi.org/10.1158/0008-5472.30029573

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading